Company Encyclopedia
View More
name
Mainz Biomed NV
MYNZ.US
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
1.935 T
MYNZ.USMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking324/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE2347.40%A
    • Profit Margin-2874.69%E
    • Gross Margin66.12%A
  • Growth ScoreD
    • Revenue YoY-28.05%E
    • Net Profit YoY15.71%B
    • Total Assets YoY15.96%A
    • Net Assets YoY160.95%A
  • Cash ScoreD
    • Cash Flow Margin-3.48%D
    • OCF YoY-28.05%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreE
    • Gearing Ratio74.27%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Mainz Biomed NV Partners with DoctorBox to Offer Home DNA Colorectal Cancer Test

    Mainz Biomed NV has partnered with DoctorBox to offer ColoAlert®, a home DNA colorectal cancer test, expanding access to at-home screening in Europe. This collaboration supports Mainz Biomed's growth strategy and emphasizes the role of digital solutions in preventive medicine.

    Reuters·
    US
    MYNZ
    +2.68%
    Reuters·
    US
    MYNZ
    +2.68%

    Mainz Biomed Signs MOU with OncoVanguard8 to Launch ColoAlert in South America

    Mainz Biomed NV has signed an MOU with OncoVanguard8 to launch its colorectal cancer screening test, ColoAlert, in South America, starting with Peru. The agreement covers commercial, legal, and regulatory terms, aiming to finalize a distribution deal soon. This AI-generated news is for informational purposes only and not financial advice.

    Reuters·
    US
    MYNZ
    +2.68%
    Reuters·
    US
    MYNZ
    +2.68%

    Mainz Biomed NV to Attend Annual Gastroenterological Working Group of Rhineland-Palatinate Meeting

    Mainz Biomed NV will participate in the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) on November 14-15, 2025, in Bad Kreuznach, Germany. The company plans to showcase its flagship product, ColoAlert, along with new diagnostic solutions focused on improving early detection of colorectal and other cancers. This announcement was originally published via GlobeNewswire on November 10, 2025.

    Reuters·
    US
    MYNZ
    +2.68%
    Reuters·
    US
    MYNZ
    +2.68%

    Mainz Biomed NV to Attend Maxim Growth Summit in New York City

    Mainz Biomed NV, a company focused on early cancer detection, will attend the 2025 Maxim Growth Summit in New York City on October 22-23, 2025. The event will include one-on-one meetings with institutional investors and senior analysts from Maxim. This announcement was originally published via GlobeNewswire on October 15, 2025.

    Reuters·
    US
    MYNZ
    +2.68%
    Reuters·
    US
    MYNZ
    +2.68%

    Mainz Biomed Update: Early Detection Test For Pancreatic Cancer Demonstrates Never Before Seen Results, Company Ready To Launch ColoAlert In Switzerland

    Mainz Biomed NV ( NASDAQ:MYNZ ) , the molecular genetics diagnostic company making a non-invasive blood-based screening test for early detection of pancreatic cancer, reported results from a feasibility study that could have widespread implications for the early detection of cancer.

    Benzinga·
    US
    MYNZ
    +2.68%
    Benzinga·
    US
    MYNZ
    +2.68%
    © 2025 Longbridge｜Disclaimer